Genmab A/S
GMABGenmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US.
Drugs in Pipeline
14
Phase 3 Programs
5
Upcoming Catalysts
2
Next Catalyst
Mar 2027
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
How GMAB's past catalysts played out
Investigator's Choice Chemotherapy
Diffuse Large B-Cell Lymphoma
Acasunlimab
Cutaneous Melanoma
Rina-S
Endometrial Cancer
Epcoritamab
Diffuse Large B-Cell Lymphoma
Zalutumumab
Head and Neck Cancer
Enapotamab vedotin (HuMax-AXL-ADC)
Ovarian Cancer
GEN1286
Advanced Solid Tumor
Acasunlimab in combination with docetaxel (in a single expansion cohort)
Solid Tumors
gemcitabine and oxaliplatin
Diffuse Large B-Cell Lymphoma
HuMax-CD4
Cutaneous T-Cell Lymphoma
GEN1042
Malignant Solid Tumor
tisotumab vedotin
Solid Tumor
Epcoritamab (monotherapy)
Diffuse Large B Cell Lymphoma
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
Breast Cancer, Breast Neoplasms
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Investigator's Choice Chemotherapy | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Acasunlimab | Phase 3 | Cutaneous Melanoma | - | - |
Rina-S | Phase 3 | Endometrial Cancer | - | - |
Epcoritamab | Phase 3 | Diffuse Large B-Cell Lymphoma | - | - |
Zalutumumab | Phase 3 | Head and Neck Cancer | - | - |
Enapotamab vedotin (HuMax-AXL-ADC) | Phase 2 | Ovarian Cancer | - | - |
GEN1286 | Phase 2 | Advanced Solid Tumor | - | - |
Acasunlimab in combination with docetaxel (in a single expansion cohort) | Phase 2 | Solid Tumors | - | - |
gemcitabine and oxaliplatin | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
HuMax-CD4 | Phase 2 | Cutaneous T-Cell Lymphoma | - | - |
GEN1042 | Phase 2 | Malignant Solid Tumor | - | - |
tisotumab vedotin | Phase 2 | Solid Tumor | - | - |
Epcoritamab (monotherapy) | Phase 2 | Diffuse Large B Cell Lymphoma | - | - |
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells. | Phase 2 | Breast Cancer, Breast Neoplasms | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Genmab A/S's drug pipeline?→
CatalystAlert tracks 14 drug candidates in Genmab A/S's (GMAB) pipeline across Phase 3, Phase 2. Its lead program is Investigator's Choice Chemotherapy (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Genmab A/S's next FDA catalyst?→
Genmab A/S's (GMAB) next tracked catalyst is a Phase 2 expected March 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GMAB biotech catalysts?→
Add GMAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Genmab A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.